Patient-Partnered Single-Cell Analysis of Rare Pediatric Disease RFA

About this funding opportunity

This RFA closed on May 24, 2022

SCIENCE GRANT RESOURCES PAGE Patient-Partnered Collaborations for Single-Cell Analysis of Rare Inflammatory Pediatric Disease

The Chan Zuckerberg Initiative invites applications from collaborative teams bringing together patient-led rare disease organizations and research teams for 4-year research projects aimed at advancing our understanding of the fundamental science of rare diseases. The Patient-Partnered Collaborations for Single-Cell Analysis of Rare Inflammatory Pediatric Disease RFA aims to support the application of single-cell biology methods to rare inflammatory pediatric diseases that will clarify cellular mechanisms of disease, understand disease heterogeneity, and improve biomarker identification or diagnostics.

Awards are $2,000,000 USD total costs for four years for each project (distributed amongst research institutions and a patient organization). The award period for each RFA is an initial two years of funding, followed by an additional two years, pending evaluation. Applicants are welcome to apply to both this opportunity and the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA"); however, the application and scope of work must be distinct.

Learn about our grantees.

Download RFA Packet\\ \\ (Opens in a new window) RFA Contact

For administrative and programmatic inquiries, or other questions pertaining to this RFA, please contact sciencegrants@chanzuckerberg.com"). Key Dates

February 1, 2022

Application portal opens

May 24, 2022

Applications due by 5 p.m. Pacific Time

Late October 2022

Earliest notification of decisions (subject to change)

December 1, 2022

Expected start date of award period

Award period and start date: The award period for each RFA is for an initial two years of funding, followed by an additional two years, pending evaluation. The expected start date is December 1, 2022.

IMPORTANT DOCUMENTS:

Application Instructions")

Institutional Approval Form") Opportunity

This Request for Applications (RFA) seeks proposals to establish and develop collaborative networks that bring together patient organizations and researchers engaged in single-cell biology. The overarching goal is to support interdisciplinary teams as they characterize the cellular mechanisms underlying rare inflammatory diseases, including possible identification of biomarkers and elucidation of disease pathways that will clarify disease stratification or identify therapeutic opportunities. Patient organizations are expected to be active collaborators on this research opportunity and full partners in the development of the grant application to directly inform research questions that will have the greatest impact on rare disease patients, and to engage in study design, patient engagement, and research dissemination. Applications for this funding opportunity should be focused on single-cell analysis of rare pediatric diseases with a specific interest in clarifying those with a distinct or primary inflammatory pathology. This opportunity builds on our current efforts to support single-cell technology and community development in our work with the Human Cell Atlas (HCA) (Opens in a new window)") and related research communities, alongside our learnings from our Rare As One Network") of patient-led rare disease organizations as they build and strengthen their organizational and scientific capacities to advance progress against rare disease. This new network will build on and integrate with our Pediatrics") and Inflammation") single-cell research networks, as well as our Rare As One Network"). To learn more, read our Medium posts on rare disease, inflammation, and pediatrics.

Project Specifications

Rare diseases can be particularly difficult to study due in part to the high degree of heterogeneity of the diseases, often seen within small and dispersed patient populations. Rare diseases classified by associated genetic variation in distinct patients may impact a…

Topic areas: Life Sciences and Health, Social Innovation and Community Development.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are accepted on a rolling basis; there is no single fixed deadline.

Who can apply

This opportunity is open to the following applicant types:

• Not specified by the program.

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

Patient-Partnered Single-Cell Analysis of Rare Pediatric Disease RFA is administered by Chan Zuckerberg Initiative (CZI), listed via Chan Zuckerberg Initiative.